So if the results point towards readily manageable CHF, improved ejection fractions etc, plus a clear difference in adverse events at 12 months, reduced hospitalisation etc that were not there in the 2a trial at 1/6 the dose, where would the SP land?
I would expect at least some of the above otherwise why bother accepting such a late report to the conference. Something in there that could point to a change in accepted clinical practice.
All Aboard, page-4
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |